+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
MALE
ID05568719

Long-Term Safety and Effectiveness Study of Prior Single-Dose Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec Treatment in Men with Hemophilia A or B

Led by Pfizer · Updated on 2026-10-07

173

Participants Needed

39

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to understand the long-term safety and effectiveness of two gene therapies, giroctocogene fitelparvovec and fidanacogene elaparvovec, in patients with Hemophilia A or Hemophilia B who have previously received these treatments through Pfizer-sponsored clinical trials. The study collects data based on standard medical care without administering any new investigational products. Participants in this study have already been treated with one of the two gene therapies in prior studies and will not receive additional experimental treatments in this trial. Instead, the study involves ongoing observation and data collection related to their health status, including diagnostic testing for liver-related conditions when clinically indicated. During the study, participants will attend visits aligned with their routine care where researchers will assess outcomes such as the incidence of blood clots, development of inhibitors, liver abnormalities, and factor activity levels over a period of up to 10 years. Additional measures include bleeding rates, factor consumption, autoimmune disorders, and quality of life assessments, ensuring comprehensive long-term monitoring of safety and effectiveness.

CONDITIONS

Brief Title

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here